Objective To determine whether active renin and endothelin levels in venous plasma differ between patients with renal artery stenosis and patients with primary hypertension. Among the patients with renal artery stenosis we also compared active renin and endothelin levels between subjects who had been cured or whose blood pressure had Improved after treatment of the stenosis and those without a beneficial reaction after such treatment.
Introduction
The endothelins are vasoactive peptides of which up to now three different isopeptides have been identified. Endothelin-1 (ET-1) is a potent vasoconstrictor produced by endothelial cells [1] , In the kidney it is produced both in endothelial and in non-endothelial cells [2] . No storage granules of E T -1 have been discovered thus far and approximately 25% of E T -1 synthesized is sccreted into the general circulation [3] . Endothelins have been thought to have a considerable impact on the vascular tone both in normal physiological and in diseased states, How ever, plasma endothelin levels have not been found to be elevated in essential hypertension [4, 5] . Endothelin levels are elevated in pulmonary hypertension and renal failure [5, 6] . Because vasoactive substances take such an important part in the pathophysiology of renovascular hypertension (RVH), it is worth considering whether endothelins are involved in at least some of the vascular reactivity mechanisms operating in this form of high blood pressure. » Specific information about the role of endothelin in RVH is, however, incomplete. Several findings suggest that endothelin could be involved in RVH through involve ment with the renin-angiotensin system. First, endothe lial cell culture studies have shown that hypoxia [7] and angiotensin II (Ang II) induce synthesis and release of endothelin [8] . Angiotensin converting enzyme (AGE) inhibition attenuates this release [9] , Second, Ang II stim ulates endothelial production of endothelin and thereby potentiates contractions in response to noradrenaline in mesenteric resistance arteries of spontaneously hyper tensive rats [10] . Furthermore, Sventek et al. [11] found vascular overexpression of E T -1 gene in one-kidney, one clip hypertensive rats but only during the late phase of two-kidney, one clip hypertensive rats. Also several clinical studies have been reported but they produced contradictory results in which endothelin levels were found to be either normal or elevated in patients with renal artery stenosis (RAS) [12] [13] [14] [15] ,
The aim of the present study was to investigate a poss ible role of endothelin in the pathophysiology of RVH in humans. We studied endothelin and renin levels in peripheral venous blood before and after ACE inhibition in members of the following groups of hypertensive patients: subjects with essential hypertension, persons with hypertension and RAS, patients whose hypertension was cured or alleviated by percutaneous transluminal renal angioplasty (PTRA) treatment of RAS and patients whose hypertension was not lessened by PTRA treatment of RAS.
In studying these specific patient groups, we supposed that we would be able to employ AGE inhibition and responses to PTRA as tools to select out RAS patients with true RVH, allowing us to compare endothelin levels of these renovascular hypertensives with those of other hypertensives. Given the evidence on endothelin summa rized above, we hypothesized that AGE inhibition would cause not only an increase in renin levels but also, via a decrease in Ang II levels, a decrease in circulating endothelin levels in patients with RVH. Furthermore, the renin: endothelin level ratio before and after AGE inhi bition could provide a reliable marker for distinguishing true RVH from essential hypertension cases with and without RAS. mercury sphygmomanometer with the patient supine. The mean of three consecutive readings was used. The possibility that these patients had other forms of second ary hypertension was assessed by determination of serum electrolyte levels, plasma renin activity, aldosterone levels and catecholamine levels. Urinary excretions of creatinine, metanephrines and protein were also measured. Endo genous creatinine clearance was calculated from serum creatinine level measurements [16] , The urine screenings, together with microscopy of urine sediments were used to exclude the possibility that these patients had parenchymatous renal disease. Patients with other forms of secondary hypertension and patients with renal in sufficiency were excluded from this study. For determi nation of plasma concentrations of active renin and endothelin, venous blood was collected into tubes containing EDTA. Samples were centrifuged immedi ately at 0°C and stored at -20°C until assay. Active renin and endothelin-1 levels were measured by radioim munoassays, as described previously [17, 18] , The anti serum for endothelin-1 exhibited 67% cross-reactivity with endothelin-2 and 84% with endothelin-3. PTRA was performed as a standard procedure via the femoral approach under direct high-resolution fluoroscopy. The reactions of blood pressure to the procedure were deter mined according to the internationally accepted criteria. A patient with blood pressure below 90 mmHg without medication was considered cured. Improvement was defined as a decline in blood pressure by at least 15% with the same medication or a decline by 10% with discontinuation of administration of at least one anti hypertensive drug. Patients who had been cured and patients who had improved were placed in the success fully treated group and all patients with other outcomes in the unsuccessfully treated group. A stenosis was consid ered significant if the vascular lumen was found by angio graphy to have narrowed by more than 50%. PTRA was performed in patients with RAS for whom there was no contra-indication to the treatment and who consented to be subjected to the procedure. Patients were adminis tered 300 mg acetylsalicylic acid a day starting 1 day before the procedure and continuing for 3 months after wards.
Patients and methods
For 52 hypertensive patients newly referred to the out patient clinic, the physicians in charge deemed it neces sary to perform intra-arterial digital subtraction angio graphy. Indications for angiography were treatment-resistant hypertension, defined as blood pressure values above 160/90 mmHg despite two-drug treatment, and other clinical clues suggestive of RAS, such as an abdominal bruit and a sudden rise of a known blood pressure.
Clinical and biochemical data of these patients were col lected. Blood pressure was measured by using a standard
Statistical analysis
Values are expressed as medians (ranges) unless indicated otherwise. Comparisons of the data within groups were analysed by Wilcoxon's paired signed rank test for para meters with non Gaussian distributions. Student's paired t test was used for parameters with normal distributions. Differences between groups were assessed by unpaired tests. When appropriate the Bonferroni correction for multiple comparisons was applied. The correlations of endothelin levels in members of the RAS, the primary hypertension, the successfully treated and the unsuc cessfully treated groups either with renin level or with endogenous creatinine clearance were analysed by Spearman's rank correlation test. Statistical significance was assumed at a 5% level, two-sided.
Results
Of the 52 patients with hypertension who had undergone diagnostic digital subtraction angiography, 25 had no RAS and were diagnosed as having essential hypertension. The remaining 27 patients proved to have RAS. There were 20 unilateral and seven bilateral cases. The clinical char-
The baseline renin level in members of the RAS group was significantly higher than that in members of the essential hypertension group [40.2 jxu/ml (0.9-543) and 13 
Furthermore, atherosclerosis was the major aetiological factor for RAS in our study rather than fibromuscular dysplasia (FM D, 20 versus seven patients). to 1528) and members of the group with essential hyperalso the five women in the successfully treated group. Thus, although male patients with atherosclerotic RAS were distributed evenly between the successfully and unsuccessfully treated groups, the female patients with atherosclerotic RAS did not respond to treatment by PTRA. tension [3.1 jxu/ml (-106 to 500)]. This also held true for the successfully treated group [47 jjuuml (-2 to 1528) and the unsuccessfully treated group [50 jui/ml (-28 to 847)]. The relative differences between baseline values and those after ACE inhibition were not significant for any of the groups. 
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Comparison of circulating endothelin levels in patients with hypertension before and after angiotensin converting enzyme (ACE) inhibition.
Horizontal bars, medians.
The patients with essential hypertension had a baseline endothelin level of 5.0 pg/ml (1.5-8.0) and the subjects with RAS had a baseline endothelin level of 3.6 pg/ml (1.4-1.7), which values were not significantly different (Fig. 1) . In members of the successful treatment group baseline endothelin level was 3.6 pg/ml (1.8-8.9 ) and in members of the unsuccessful group it was 3.75 pg/ml (1.4-8.3); also these values were not significantly different (Fig. 2) .
ACE inhibition caused no significant change in endothelin levels in members of any of the four study groups. Furthermore, the differences and relative differences in endothelin levels before and after ACE inhibition did not differ significantly between members of die RAS group and the essential hypertension group and between members of the successfully and the unsuccessfully treated groups.
The renin : endothelin level ratio at baseline was signi ficantly higher for the RAS group in comparison with that for the essential hypertension group The renin : endothelin level ratio at baseline was the same for the group that responded as it was for the group that did not respond to treatment by PTRA. Furthermore, ACE inhibition failed to cause a significant difference between values of this ratio for these patient groups. The difference in ratios before and after ACE inhibition did not differ significantly between the successfully and unsuccessfully treated groups.
Endothelin levels in peripheral venous blood were not correlated either to renin levels or to endogenous creati nine clearances for all four groups.
Discussion
The results of the present study indicate that endothelin levels in peripheral venous blood under baseline resting conditions are comparable among patients with essential hypertension, hypertension combined with RAS and RVH. In addition, ACE inhibition and thus a decrease in Ang II levels did not affect endothelin levels in patients with essential hypertension, patients with essential hyper tension combined with RAS and patients with RVH. Although the renin : endothelin level ratio differed signif-Endothelin and active renin levels Teunissen et a/. 1795 
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Comparison of circulating endothelin levels in patients for whom percutaneous transluminal renai angioplasty had been successful and unsuccessful at lowering blood pressure before and after angiotensin converting enzyme (ACE). Horizontal bars, medians.
icantly between the groups with and without RAS, this was largely, if not completely, due to the significant differ ence in renin levels. This argument also applies to the renin : endothelin level ratio after ACE inhibition, which displayed an even more significant difference.
In dividing the group of patients with RAS into those who responded to PTRA and those who did not* we attempted to distinguish between RAS leading to RVH and RAS occurring concomitantly with essential hyper tension. Interestingly, among the patients with RAS, administration of the ACE inhibitor caused renin levels to rise only in members of the group who responded to treatment by PTRA. Therefore, the fact that endothelin levels did not differ between these groups and were not affected differently by ACE inhibition makes the hypoth esis that endothelin plays a role in the pathophysiology of RVH less plausible.
It is possible that the production and release of endothelin were not affected during the relatively short 60 min sampling period used in this study. However, an oral dose of captopril reaches its maximum plasma level 1 h after ingestion and the maximum blood-pressure-lowering affect occurs 60-90 min after ingestion. Thus it can be concluded that, 60 min after ingestion, while captopril is affecting the renin-angiotensin system and other mechan isms involved in regulation of blood pressure, regulation of endothelin production seems not to be altered.
Plasma levels of endothelin both in essential hypertension and in RVH patients both with and without ACE inhi bition have been investigated by several other groups.
Results of most studies [12] [13] [14] [15] concur with the results of the present study. Two groups who studied endothelin levels in blood samples taken directly from renal arteries and veins found endothelin levels in healthy controls, patients with essential hypertension and patients with RAS to be within the normal range [14, 15] . Januszewicz et al. [19] reported that the degree of activation of the renin-angiotensin system had no effect on the endothelin levels, which were also not elevated in their patients with RAS. In contrast, Giussani et al. [12] did find an increase in plasma endothelin levels in patients with RAS and elevated Ang II levels.
Several in-vitro studies with isolated arteries from rats and humans have shown that the vasocons trie ting effect of infusion of endothelin-1 on vascular smooth muscle cells is blunted in subjects with mild forms of hypertension [19] [20] [21] . Furthermore, vascular smooth muscle cells from spontaneous hypertensive rats display lower than normal responses of intracellular calcium levels to infusion of endothelin-1 but exhibit higher than normal responses to infusion of Ang II [22, 23] . These results suggest that endothelin does not affect vasoreactivity once hyper tension has been established and thus possibly this could explain why endothelin levels are not elevated in most hypertensive (patients with essential hypertension and patients with RVH) subjects studied. Possibly endothelin plays a role in vasoreactive events leading to chronic hypertension. However, Sventek et al. [11] recently showed that, although the one-kidney one clip Goldblatt hypertensive rat exhibits vascular overexpression of the endothelin-1 gene, the two-kidney, one clip Goldblatt hypertensive rat only does so during a late phase. This late expression could also be linked to renal failure or to an inability of the lungs or kidneys to clear the endothelin. Thus, although many studies, including the present one, could not show that circulating endothelin plays a role in maintaining RVH, endothelin's role in the early phase of RVH has yet to be sufficiently studied.
With the exception of baseline systolic blood pressure, there were no significant differences among the clinical characteristics of the groups studied. Male and female patients were distributed equally among groups. In a recent study [24] it was found that plasma endothelin levels are modulated by the menstrual cycle. Although this new knowledge does not directly affect the results of the present study, all future studies of this type should take the effect of the menstrual cycle on endothelin levels into consideration when experimenting on female subjects. O f the 27 patients with RAS, seven were diag nosed as having bilateral stenosis. Furthermore, four of the unsuccessfully and one of the successfully treated patients had bilateral RAS. In such cases, both renal arteries were treated by PTRA. It was, however, beyond the scope of this study to evaluate the difference between unilateral and bilateral stenosis with regard to hyper tension, renin levels and endothelin levels.
In conclusion, the present study showed that circulating levels of endothelin in patients with essential hyper tension, patients with hypertension with RAS and patients with true RVH are similar. Although the reninangiotensin system in patients with RVH was activated, as shown by a significant increase in plasma renin activity after AGE inhibition, endothelin levels were not corre lated co the renin levels and were not affected by AGE inhibition. These results do not support the hypothesis that production of endothelin in RVH patients is depen dent on Ang II.
